ASCO 2022 Summary of findings in oncology and China market


China is never a new word in ASCO. China-originated innovation made its ASCO debut in 2011, and since then we have been seeing more Chinese pharma bringing exciting clinical progress in the oncology space. This year, there will be 19 oral presentations and more than 70 posters from Chinese pharma, with the keyword 'China’ hit a record high of nearly 350 times in the ASCO Agenda.

Go to Top